The GRACE study (Gender Race And Clinical Experience) is now recruiting participants for the largest clinical study to date in treatment-experienced adult women with HIV to evaluate gender and race differences in response to an HIV medication.  The study's sponsor, Tibotec Therapeutics Clinical Affairs, a division of Ortho Biotech Clinical Affairs, LLC, is seeking to raise awareness among African-American women of the trial and its importance to the treatment of HIV.  GRACE, a multi-center, open-label Phase IIIb trial, will compare gender differences in the efficacy, safety and tolerability of PREZISTA (darunavir) tablets administered with ritonavir and other antiretroviral agents over a 48-week period.  The study also will explore racial differences in treatment outcomes.  Eligibility is open to men and women of all races.  Participants must be of 18 years or older, have a viral load of 1000 copies/mL or greater and have previous intolerance or failure of prior therapy consisting of a protease inhibitor and/or non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral treatment regimen of at least 12.  All participants will receive PREZISTA/r (600/100mg twice a day) with an optimized background regimen chosen by the investigator and based on resistance testing and prior treatment history.  For additional information click here or call 1-866-512-7943.